Previous 10 | Next 10 |
ADC Therapeutics SA (ADCT) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 ET Company Participants Amanda Hamilton - IR Officer Christopher Martin - Co-Founder, CEO & Director Jennifer Herron - Chief Commercial Officer & SVP Jay Feingold - Chief Medical Officer, Head, Oncology Cl...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q1 2021 Earnings Call May 06, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript
ADC Therapeutics (ADCT): Q1 GAAP EPS of -$0.74 beats by $0.17.Cash and cash equivalents were $383.1 million as of March 31, 2021, compared to $439.2 million as of December 31, 2020. In the coming days, the Company will be drawing down $50 million associated with its Convertible Credit Facilit...
- ZYNLONTA™ (loncastuximab tesirine-lpyl) granted accelerated FDA approval for patients with relapsed or refractory diffuse large B-cell lymphoma - Commercial launch progressing well; orders shipped - NCCN guidelines category 2A recommendation to reflect the bro...
- ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hema...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside ch...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, May 6, 2021...
ADC Therapeutics' (ADCT) just approved Zynlonta (loncastuximab tesirine-lpyl) is a "best in class" therapy for diffuse large B-cell lymphoma ("DLBCL"), according to Cowen.Analyst Boris Peaker has an outperform rating and expects FY 2021 sales of $26M.Other FDA-approved DLBCL t...
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, includ...
The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics (ADCT) for diffuse large B-cell lymphoma.The biologic was given Priority Review status and approved ahead of its PDUFA date of May 21, 2021.ADC also has an expanded access program for Zynlonta.ADC shares are ...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...